Win in Vioxx case is sixth for Merck

Share this article:
A federal jury in New Orleans found in favor of Merck, rejecting a claim that Vioxx caused a man’s 2003 heart attack. The case marked the 11th for Merck involving the withdrawn pain drug. Of these it has won six—including three out of four federal cases—and lost four. (A remaining trial in New Jersey was rescheduled after being overturned.) The company still faces about 24,000 lawsuits and has pledged to address them on an individual basis. The plaintiff in the latest federal case, Charles Laron Mason, took Vioxx for about 10 months before his heart attack but admitted he had not taken it in the days before his heart attack. The jury determined that Merck acted appropriately in the development and marketing of Vioxx and that the drug did not substantially contribute to Mason’s heart attack. Vioxx was withdrawn in 2004 after a study linked it to heart risks. Mason has not decided whether to appeal, his lawyer told the Associated Press. US District Court Judge Eldon Fallon, who is overseeing all of the federal Vioxx litigation, said he wants to press for a settlement after the next federal case, The Wall Street Journal reported.
Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...